Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LUNG ULTRASOUND CAN PREDICT THE CLINICAL COURSE AND SEVERITY OF COVID-19 DISEASE

CECILIA GÓMEZ RAVETTI,* PAULA FRIZERA VASSALLO,† GUILHERME MONTEIRO DE BARROS,‡,§
GUILHERME CARVALHO ROCHA,* SAMUEL CHAMON,* ISABELA NASCIMENTO BORGES,*
CAROLINA COIMBRA MARINHO,* MÁDERSO ALVARES DE SOUZA CABRAL,* HELENA DUANI,*
MARCUS VINICIUS MELO DE ANDRADE,*
VANDACK NOBRE* and on behalf of the Núcleo de Investigação em Medicina Intensiva (NIIMI)

*Department of Internal Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; †Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; ‡Empresa Brasileira de Serviços Hospitalares, Belo Horizonte, Brazil; and §Postgraduate Program in Health Sciences, Infectious Diseases and Tropical Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

(Received 10 November 2020; revised 2 March 2021; in final from 26 April 2021)

Abstract—Coronavirus disease 2019 (COVID-19) compromises the lung in large numbers of people. The development of minimally invasive methods to determine the severity of pulmonary extension is desired. This study aimed to describe the characteristics of sequential lung ultrasound and to test the prognostic usefulness of this exam in a group of patients admitted to the hospital with COVID-19. We prospectively evaluated patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection admitted to our hospital between April and August 2020. Bedside lung ultrasound exams were performed at three time points: at inclusion in the study, after 48 h and on the seventh day of follow-up. Lung ultrasound scores were quantified according to the aeration loss in each of eight zones scanned. Sixty-six participants were included: 42 (63.6%) in the intensive care unit and 24 (36.3%) in the ward. Lung ultrasound scores were higher in participants admitted to the intensive care unit than in those admitted to the ward at the time of inclusion (16 [13–17] vs. 10 [4–14], p < 0.001), after 48 h (15.5 [13–17] vs. 12.5 [8.2–14.7], p = 0.001) and on the seventh day (16 [14–17] vs. 7 [4.5–13.7], p < 0.001) respectively. Lung ultrasound score measured at the time of inclusion in the study was independently associated with the need for admission to the intensive care unit (odds ratio = 1.480; 95% confidence interval, 1.093–2.004; p = 0.011) adjusted by the Sequential Organ Failure Assessment score.

Key Words: COVID-19, Lung ultrasound, Intensive care, SARS-CoV-2.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was first described in China in December 2019, and rapidly spread worldwide. Today, coronavirus disease 2019 (COVID-19), the disease caused by the new beta coronavirus, affects more than 37 million people around the world, and more than one million have died (WHO, 2020). COVID-19 diagnosis requires isolation of RNA from clinical samples or a high clinical suspicion associated with typical images on chest computerized tomography, such as peripheral ground-glass opacities mainly in the lower regions of the lungs (Fang et al. 2020).

In critically ill patients, with severe hypoxemia requiring mechanical invasive ventilatory support, transport for chest imaging is both clinically dangerous and associated with a higher risk of virus transmission during transportation (Simpson et al. 2020). Bedside lung ultrasoundography (LUS) has proven useful for evaluating COVID-19 patients, with several studies describing the main characteristic findings of this exam (Convissar et al. 2020; Peng et al. 2020; Soldati et al. 2020). As it is non-invasive and does not expose patients to ionizing radiation, LUS is an excellent alternative to other methods of diagnosing and monitoring the pulmonary...
condition of patients with suspected or confirmed COVID-19. Moreover, it may reduce the need for patient transport and its related risks.

Lichter et al. (2020) showed that LUS score measured at admission strongly correlates with the need for invasive mechanical ventilation and mortality in people infected with SARS-CoV-2. That study included 120 participants, but only 20 were sequentially screened with a second exam.

Perrone et al. (2020) also evaluated COVID-19 patients admitted to wards, analyzing 14 windows at two time points: admission and discharge. The study included 52 participants, and observed a positive correlation between LUS score and worsening disease.

The present study aimed to describe the characteristics of sequential LUS and to test the prognostic usefulness of this exam in a group of patients admitted in a tertiary hospital, both intensive care units and wards, with suspected COVID-19.

METHODS

This study was carried out at Hospital das Clínicas, Universidade Federal de Minas Gerais. We used a convenient sampling protocol to include patients admitted between April and August 2020. During this period all adults (age ≥ 18 y) admitted to the units dedicated to the care of COVID-19 patients (a 23-bed ward and an 18-bed intensive care unit [ICU]) were assessed for potential eligibility. Exclusion criteria were COVID-19 non-confirmation by reverse transcription polymerase chain reaction, a more probable differential diagnosis at the time of inclusion, exclusive palliative care at the moment of first assessment for the study and high probability of death within 24 h of inclusion. The local ethics committee approved the study (protocol number 30437020.9.3001.5124), and all participants signed an informed consent form.

The first priorities to admit patients to the ICU were hemodynamic instability with noradrenaline requirement (>0.1 μg/kg/min), acute kidney injury with hemodialysis requirement, endotracheal intubation for invasive mechanical ventilation and post-cardiac arrest. Secondary priorities were median arterial pressure <65 mm Hg or systolic blood pressure <90 mm Hg, oxygen saturation <93% in room air, pulmonary infiltration rapidly progressive (50% in 24–48 h) and National Early Warning Score ≥ 7.

Clinical and epidemiologic data were prospectively collected using electronic charts. The prevalence of comorbidities such as chronic obstructive pulmonary disease, asthma, systemic arterial hypertension, heart failure, diabetes mellitus, coronary artery disease, obesity, solid organ neoplasm, hematological neoplasm, solid organ or hematopoietic stem cell transplantation and chronic renal replacement therapy requirement was also registered. Finally, we calculated the Sequential Organ Failure Assessment (Vincent et al. 1996) score for all participants included in the study, and the APACHE II (Knaus et al. 1985) score in those admitted to the ICU.

Ultrasound exams were performed at three time points, with 3–4 s image acquisition (recorded) in each area: at inclusion in the study, after 48 h and on the seventh day after inclusion. The images were acquired by the same physician, who is experienced in intensive care and in performing point-of-care ultrasound examinations at the bedside (Gómez Ravetti et al. 2020). The US protocol was adapted from Soummer et al. (2012) and included four areas in each hemithorax: anterior (2˚ inter-costal space at a mid-clavicular line), lateral (anterior axillary line at 5˚ inter-costal space), posterior (posterolateral axillary or pleural syndrome) and costophrenic (Fig. 1).

A Terason t3000 portable ultrasound machine (Terason Ultrasound, Burlington, MA, USA) and Sonosite M-Turbo (Sonosite, Bothell, WA, USA) were used with a sector transducer (3.5–5 MHz). The depth was adjusted between 5 and 10 cm at the beginning of the exam. In lateral areas, according to visualized costophrenic zones, some deeper images were obtained (15 cm) to determine the presence of pleural effusion and

Fig. 1. Thorax ultrasound protocol regions scanned.
consolidation. For better visualization of the pleura, a linear probe (5–10 MHz) was used whenever required. The linear probe was mainly used to diagnose or rule out pneumothorax or barotrauma related to mechanical ventilation.

According to the images found in each assessed area, pulmonary aeration was quantified through a previously defined scoring rubric (Sousummer et al. 2012): 0 points for A-lines with lung sliding, 1 point for more than three well-defined B-lines, 2 points for coalescent B-lines, 3 points for consolidation and 1 point if pleural effusion is present in each hemithorax. A B-line was defined as a vertical, hyperechoic, dynamic line that originates in the pleural line and moves synchronously with lung sliding. A well-defined B-line pattern was characterized by more than three B-lines in an intercostal space which the operator could count. Coalescent B-line patterns were characterized by B-lines that the operator could not quantify because they were so numerous and tended to merge (Fig. 2). The score ranged from 0 to 26 points, with higher values meaning greater loss of aeration.

Statistical analysis

Data are described as proportion, central tendency and distribution. Qualitative variables were compared with \( \chi^2 \) or Fisher’s exact test, as recommended. Quantitative variables were compared by the Mann–Whitney U test or Kruskal–Wallis test, as indicated according to normal or non-normal distribution. The Friedman test was used to compare quantitative variables within the same group. To investigate whether LUS was associated with outcome, we built a logistic regression model. All explanatory variables with a \( p < 0.05 \) were included in this model. Moreover, we built a Kaplan–Meier survival curve according to the LUS score and compared it with a log-rank test. LUS score was included as a dichotomous variable for which the cutoff was set using a receiver operating characteristic curve and the Youden test.

A two-tailed \( p \) value <0.05 was considered significant for all analyses. The REDCap platform (REDCap, Nashville, TN, USA) was used to collect the data, and SPSS version 22.0 (IBM, Chicago, IL, USA) was used for statistical analysis.

RESULTS

We assessed 82 patients for eligibility, and 66 with confirmed SARS-CoV-2 infection were included in the final analysis. COVID-19 diagnosis was confirmed by reverse transcription polymerase chain reaction test by nasopharyngeal swab in most participants (93.3%), or combination of a highly suggestive clinical scenario and
typical findings on chest computed tomography in the rest. Forty-two participants (63.6%) were admitted to the ICU and 24 (36.3%) to the ward. The median (interquartile range) age was 63.5 (46.7–72) y; 30 (45.5%) were female and 36 (54.5%) male. The most common comorbidities were hypertension (59.1%), diabetes mellitus (34.8%) and obesity (24.2%). Dyspnea was present at hospital admission in more than 80% of participants. Thirty-three (78.6%) of the 42 participants admitted to the ICU were mechanically ventilated, and 23 (69.7%) of those 33 died. The overall hospital mortality in the study sample was 36.9%, and the mortality in the subgroup initially admitted to the ICU was 58.5%. Taken as a whole, the ICU group had dyspnea more frequently, had higher Sequential Organ Failure Assessment scores on admission and spent more time in the hospital than those admitted to the ward (Table 1).

**LUS according to admission destination at the time of inclusion**

LUS scores were significantly higher among participants initially admitted to the ICU than those admitted to the ward; these differences were observed at the time of inclusion, on day 3 and on day 7 (Fig. 3).

We further compared the tendency of LUS scores measured on days 1, 3 and 7 between the two groups. There was no significant within-group difference in participants admitted to the ward (respectively, 10 [4–14], 12.5 [8.2–14.7] and 7 [4.5–13.7]; p = 0.152) or to the ICU (16 [13–17], 15.5 [13–17] and 16 [14–17]; p = 0.583).

In an analysis adjusted for severity (i.e., Sequential Organ Failure Assessment score), the LUS score measured at the time of inclusion in the study was independently associated with the need for ICU admission (odds ratio = 1.480; 95% confidence interval, 1.093–2.004; p = 0.011).

**LUS findings stratified by the need for ICU admission**

The LUS artifacts (A-lines, well-defined B-lines, coalescent B-lines and consolidation) for each Table 1. Demographic and clinical characteristics of participants

| Characteristic | All (N = 66) | Ward (n = 24) | ICU (n = 42) | p   |
|---------------|--------------|--------------|--------------|-----|
| Age (y)       | 63.5 (46.7–72) | 60 (46–70)  | 64 (50–72)  | 0.323 |
| Male sex      | 36 (54.5)     | 10 (41.7)    | 26 (61.9)    | 0.112 |
| Comorbidities | 60 (90.9)     | 22 (91.7)    | 36 (85.7)    | 0.700 |
| Hypertension  | 39 (59.1)     | 12 (50)      | 27 (64.3)    | 0.256 |
| Diabetes      | 23 (34.8)     | 8 (33.3)     | 15 (35.7)    | 0.845 |
| Obesity       | 16 (24.2)     | 4 (17.4)     | 12 (29.3)    | 0.292 |
| COPD/Asthma   | 12 (18.8)     | 5 (20.8)     | 7 (16.7)     | 0.618 |
| HF            | 6 (9.4)       | 2 (8.3)      | 4 (9.5)      | 1.000 |
| Cardiovascular disease | 10 (15.1) | 5 (20.8) | 5 (11.9) | 0.477 |
| Solid neoplasm | 10 (17.2)   | 3 (12.5)     | 7 (16.7)     | 0.736 |
| Solid organ transplantation | 7 (10.6) | 4 (16.7) | 3 (7.1) | 0.246 |
| Symptoms      |              |              |              |      |
| Dyspnea       | 54 (81.8)     | 13 (54.2)    | 41 (97.6)    | <0.001 |
| Cough         | 47 (71.2)     | 18 (75)      | 29 (69)      | 0.607 |
| Fever         | 38 (57.6)     | 15 (62.5)    | 23 (54.8)    | 0.541 |
| SOFA score    | 4 (2–7)       | 1.5 (1–3)    | 5 (3–9)      | <0.001 |
| Leukocyte count (× 10³) | 9.09 (5.02–11.89) | 5.58 (3.58–8.81) | 10.52 (7.84–13.55) | <0.001 |
| Neutrophil count (× 10³) | 7.57 (3.48–9.97) | 3.54 (2.28–6.67) | 8.60 (5.62–11.87) | <0.001 |
| Lymphocyte count (× 10³) | 0.81 (0.58–1.38) | 1.09 (0.60–1.62) | 0.74 (0.58–1.08) | 0.080 |
| CRP (mg/L)    | 158 (60–215)  | 81 (52–163)  | 175 (71–233) | 0.011 |
| LOS (d)       | 14 (7.2–26.7) | 13 (6–16)    | 18 (10–33)   | 0.032 |
| Dexamethasone | 38 (59.4)     | 9 (37.5)     | 31 (73.8)    | 0.004 |
| ATB use       | 62 (93.9)     | 20 (83.3)    | 42 (100)     | 0.015 |
| IMV requirement | 33 (50)   | 0            | 33 (78.6)    | <0.001 |
| Hospital mortality | 24 (36.9)   | 0            | 24 (58.5)    | <0.001 |

COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; ICU = intensive care unit; IMV = invasive mechanical ventilation; LOS = length of stay; SOFA = Sequential Organ Failure Assessment; ATB = antibiotics; HF = heart failure.

Data are presented as number (%) or median (interquartile range).
pulmonary region assessed at the time of inclusion in the study were compared according to the need for ICU or ward admission. Participants admitted to the ward showed more prevalence of A lines in the right and left hemithorax in the eight windows than those admitted to the ICU (Fig. 4). Likewise, the ICU group showed more B-lines (well defined and coalescent) in upper windows (R1, R2, R3, L1, L2 and L3) than the ward group.

Accordingly, median LUS scores were significantly higher among participants who died during hospitalization than those who did not on day 1 (16 [14–17] vs. 12 [8–16], p = 0.001), day 3 (15.5 [13–17.7] vs. 14 [11–16], p = 0.025) and day 7 (15 [14.2–17] vs. 14 [6.7–16], p = 0.029).

Mortality among participants with LUS scores > 12 at inclusion was significantly higher than among those with lower scores (2 [83%] vs. 22 [91.7%], p < 0.001), and their cumulative survival during follow-up was significantly lower (Fig. 5).

DISCUSSION

In this study, a LUS score for pulmonary aeration loss quantified at bedside was independently associated with the need for ICU admission among patients admitted with COVID-19, adjusted by the severity. Also, sequential lung scores measured after 48 h and on the seventh day of follow-up were higher in those admitted to the ICU than those in the ward. Likewise, the ICU group showed more prevalence of B-lines in the upper lung regions.

Since the beginning of the pandemic, several studies on LUS in COVID-19 have been published (Buonsenso et al. 2020; Peng et al. 2020;...
Our findings on LUS are in agreement with previously published data showing impaired aeration predominantly in posteroinferior regions, identified by the presence of B-lines with different patterns—from well-defined B-lines to coalescence (“white lung”)—pleural “thickening” and subpleural consolidations (Smith et al. 2020; Volpicelli et al. 2020; Xing et al. 2020).

Lichter et al. (2020) carried out a study with LUS in 120 COVID-19 patients. They performed a first exam at the time of hospital admission in all participants, and a second exam in a subgroup of 20 participants who required orotracheal intubation. This study demonstrated that the pulmonary score measured at admission was associated with the composite outcome of need for invasive mechanical ventilation or death. These findings are in line with our results showing more significant loss of aeration in patients who required ICU admission and died during hospitalization.

Bonadia (2020) demonstrated in 41 patients with COVID-19 that in the first ultrasound exam performed at the emergency department, the rates of pathologic lung areas involved and the scores of aeration loss were higher among those who were admitted to the ICU or died during hospitalization.

Bonadia (2020) demonstrated in 41 patients with COVID-19 that in the first ultrasound exam performed at the emergency department, the rates of pathologic lung areas involved and the scores of aeration loss were higher among those who were admitted to the ICU or died during hospitalization. These findings are in line with our results showing more significant loss of aeration in patients who required ICU admission and died during hospitalization.

Our study sequentially evaluated lung ultrasound in a larger number of COVID-19 patients with different disease severities, assessed at three time points. We hypothesized that by doing so, we would be able to monitor the evolution of lung compromise (i.e., aeration loss) during the first week of the disease, which could help predict the need for ICU admission and eventual death. Our data suggest that LUS findings can be added to other clinical and laboratory data to render the decision-making process regarding care management more accurate. In other scenarios of severe pulmonary disease, pulmonary ultrasonography has proven useful, both in diagnosis (Lichtenstein and Mezière 2008) and in monitoring positive end-expiratory pressure adjustment (Bouhemad et al. 2011) and the response to antibiotic treatment in cases of ventilator-associated pneumonia (Bouhemad et al. 2010). Previous studies have demonstrated the evolution of pulmonary lesions in the convalescence period, from consolidation to A-line patterns (Peng et al. 2020; Xing et al. 2020). Using this method in a systematic protocol would avoid patient transport for computed tomography scans, as well as the exposure of health workers to chest X-ray. Moreover, in low-resource environments and remote areas such as the Amazon region, LUS can be a portable alternative to help manage COVID-19.

Our results highlight the importance of performing a bedside lung ultrasound to determine disease severity and to quantify aeration loss in patients admitted with SARS-CoV-2 infection.

Mento et al. (2020), in a multi-center study, compared four LUS protocols (4, 8, 12 and 14 scanned areas) in COVID-19 patients, and showed that 12-area acquisition had a better correlation between time scanned and accuracy. Similarly, a CLUE protocol with 12 lung areas has been recommended in COVID-19 patients, and suggested as useful in emergency-department clinicians’ decision making (Manivel et al. 2020). We quantified aeration loss differently, measuring in eight lung windows according to previous studies (Soummer et al. 2012; Millington et al. 2018) with critically ill patients, because most of our participants were admitted to the ICU. Our eight scanned zones proved to be sufficient to differentiate groups according to severity and outcomes. In our opinion, this approach could be useful in severe COVID-19.

Perrone et al. (2020) and Smargiassi et al. (2020) used 14 areas in LUS of people with COVID-19. In both studies, the authors evaluated patients admitted to the wards differently from our cohort of participants. In our study, participants were admitted mostly to the ICU, where position change required further effort, because most of them were under mechanical ventilation or had high oxygen demand. However, we scanned the whole pulmonary area and recorded 3–4 s of each area, totaling a minimum of 32 s per participant.

In this study, we used a phased-array probe to scan the lungs, as recommended for some experts with people who are critically ill (Mojoli et al. 2019), and a linear probe was used only in situations when barotrauma or pneumothorax was a concern. We hypothesized that during the COVID-19 pandemic, when health professionals’
exposure has to be limited, this approach could have underestimated disease severity, despite our results proving different between the groups.

Another limitation is that this was a single-center study with a small number of participants. However, the prospective design, along with the protocol of sequential LUS imaging in patients admitted to the hospital with COVID-19, is a positive aspect of the study, and can contribute to anticipating the need for ICU admission.

**CONCLUSION**

Bedside lung ultrasound proved to be a suitable method for determining severity of illness in people admitted to the hospital with SARS-CoV-2 infection. The lung ultrasound scores measured at three time points were higher in those who required ICU admission and died during hospitalization.

**Acknowledgments**—This work was support in part by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ministério de Educação (MEC) Brasil and Universidade Federal de Minas Gerais (UFMG).

Conflict of interest disclosure—The authors declare that there is no conflict of interest regarding the publication of this paper.

**REFERENCES**

Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med 2011;183:341–347.

Bonadía N, Carnicelli A, Piano A, Buonsenso D, Gilarde F, Kadhim C, Torelli E, Petrucci M, Di Maurizio L, Biasucci DG, Fuerlo M, Forte E, Zacaria R, Franceschi F. Lung Ultrasound Findings Are Associated with Mortality and Need for Intensive Care Admission in COVID-19 Patients Evaluated in the Emergency Department. Ultrasound Med Biol 2020;46:2927–2937.

Bouhemad B, Liu ZH, Arbelot C, Zhang M, Ferrari F, Le-Guen M, Girard M, Lu Q, Rouby JJ. Ultrasound assessment of antibiotic-induced pulmonary reaeration in ventilator-associated pneumonia. Crit Care Med 2010;38:84–92.

Buonsenso D, Tata D, Chiaretti A. COVID-19 outbreak: Less stethoscope, more ultrasound. Lancet Respir Med 2020;8:e27.

Convisser DL, Gibson LE, Berra L, Bittner EA, Chang MG. Application of lung ultrasound during the COVID-19 pandemic: A narrative review. Anesth Analg 2020;131:345–350.

Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020;296:e115–e117.

Gómez Ravetti C, Aita de TBaLS, Barreto LDm, Bastos FDl, Gomes ALGDr, Bragança RD, Marinho CC, Nobre V. Lung ultrasound is useful in oncohematologic patients with respiratory dysfunction admitted to an intensive care unit (ICU): A pilot study. Med Ultrasound 2020;22:178–182.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818–829.

Lichtenstein DA, Mezière GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: The BLUE protocol. Chest 2008;134:117–125.

Lichter Y, Topilsky Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Vine J, Goren O, Cohen B, Sapir O, Granot Y, Mann T, Friedman S, Angel Y, Adi N, Lauffer-Perl M, Ingbir M, Arbel Y, Matot I, Szekely Y. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. Intensive Care Med 2020;46:1873–1883.

Maesel V, Lesniewski A, Shamir S, Carbonatto G, Govindan T. CLUE: COVID-19 lung ultrasound in emergency department. Emerg Med Australas 2020;32:694–696.

Mento F, Perrone T, Macioce VN, Tursi F, Buonsenso D, Torri E, Smargiassi A, Incingolo R, Soldati G, Demi L. On the impact of different lung ultrasound imaging protocols in the evaluation of patients affected by coronavirus disease 2019: How many acquisitions are needed?. J Ultrasound Med 2020;1–4. doi: 10.1002/jum.15580.

Millington SJ, Arnfield RT, Guo RJ, Koenig S, Kory P, Noble V, Malmert H, Schoenherr JR. Expert agreement in the interpretation of lung ultrasound studies performed on mechanically ventilated patients. J Ultrasound Med 2018;37:2659–2665.

Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung ultrasound for critically ill patients. Am J Respir Crit Care Med 2019;199:701–714.

Peng QY, Wang XT, Zhang LN. (CCUSG) CCCUSG. Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019-2020 epidemic. Intensive Care Med 2020;46:849–850.

Perrone T, Soldati G, Padovini L, Piengo A, Lettieri G, Sabatini U, Gori G, Lepore F, Garofoli M, Palumbo I, Incingolo R, Smargiassi A, Demi L, M ossolani EE, Tursi F, Klersy C, Di Sabatino A. A new lung ultrasound protocol able to predict worsening in patients affected by severe acute respiratory syndrome coronavirus 2 pneumonia. J Ultrasound Med 2020;1–9. doi: 10.1002/jum.15548.

Simpson S, Kay FU, Abbara S, Bhatta S, Chung JH, Chung M, Henry TS, Kanpe JP, Klingerman S, Ko JP, Litt H. Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA—secondary publication. J Thorac Imagew 2020;35:219–227.

Smargiassi A, Soldati G, Torri E, Mento F, Milardi D, Del Giacomo P, De Matteis G, Buzu ML, Larici AR, Pompili M, Demi L, Incingolo R. Lung ultrasound for COVID-19 pathway pneumonia: Extended or limited evaluations?. J Ultrasound Med 2021;40:521–528.

Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19—a narrative review. Anaesthesia 2020;75:1096–1104.

Soldati G, Smargiassi A, Incingolo R, Buonsenso D, Perrone T, Briganti DF, Perlini S, Torri E, Mariani A, Mossolani EE, Tursi F, Mento F, Demi L. Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: A simple, quantitative, reproducible method. J Ultrasound Med 2020;39:1413–1419.

Souummer A, Perbet S, Brisson H, Arbelot C, Constantin JM, Lu Q, Rouby JJ. Lung Ultrasound Study Group. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress. Crit Care Med 2012;40:2064–2072.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707–710.

Volpicelli G, Lamorte A, Villem T. What’s new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med 2020;46:1445–1448.

Xing C, Li Q, Du H, Kang W, Lian J, Yuan L. Lung ultrasound findings in patients with COVID-19 pneumonia. Crit Care 2020;24:174.

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf. Accessed May, 18, 2021.